Bisphosphonate application and volumetric effects on MRONJ lesions

Max-Philipp Lentzen1, Johannes Buller1, Maximilian Riekert1

  • 1Department for Oral and Craniomaxillofacial and Plastic Surgery, University Hospital Cologne and Faculty of Medicine, University of Cologne, Germany.

Insights

Medication-related osteonecrosis of the jaw (MRONJ) lesion volumes were measured using CT scans. Intravenous antiresorptive medication correlated with significantly larger MRONJ lesions compared to oral or subcutaneous routes.

Area of Science:

  • Oral and Maxillofacial Surgery
  • Radiology
  • Pharmacology

Background:

  • Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication of antiresorptive therapy.
  • Accurate volumetric assessment of MRONJ lesions is crucial for understanding disease progression and treatment efficacy.

Purpose of the Study:

  • To analyze the volume of MRONJ lesions using semi-automatic segmentation of cone-beam computed tomography (CBCT) images.
  • To correlate lesion volume with underlying diseases and the route of antiresorptive medication administration.

Main Methods:

  • Semi-automatic segmentation of MRONJ lesions was performed on CBCT images using ITK-Snap software.
  • Volumetric measurements were analyzed based on lesion size, location, gender, underlying disease, and medication application route.
  • CBCT scans from 66 patients (34 male, 32 female) were included in the study.

Main Results:

  • Mean MRONJ lesion volume was 993.24 mm³ (upper jaw: 484.73 mm³; lower jaw: 1084.04 mm³).
  • Statistically significant differences in lesion volume were observed between the upper and lower jaws (p=0.003).
  • Intravenous (IV) antiresorptive administration resulted in significantly larger MRONJ lesions compared to oral or subcutaneous (s.c.) routes (p=0.004).

Conclusions:

  • The volume of MRONJ lesions is influenced by the route of antiresorptive medication delivery.
  • Patients receiving intravenous antiresorptive therapy are likely to develop larger MRONJ lesions.
  • Further research may explore specific antiresorptive agents and their impact on MRONJ lesion volume.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
640
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
3.6K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
762
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
216
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
497